Clozapine N-oxide (CNO): Chemogenetic Actuator for Precise Neuronal Modulation

Executive Summary: Clozapine N-oxide (CNO) is a stable metabolite of clozapine, widely used as a chemogenetic actuator for DREADDs-based neuronal modulation in mammalian systems [APExBIO]. CNO exhibits biological inertness in wild-type mammalian subjects, ensuring minimal off-target physiological effects (Peng et al., 2023). It enables highly specific activation of engineered muscarinic receptors, such as hM3Dq and hM4Di, with robust receptor selectivity [See review]. CNO is extensively benchmarked for reducing 5-HT2 receptor density and modulating phosphoinositide hydrolysis in neuronal cultures. It is supplied as a powder, optimally soluble in DMSO at >10 mM, with best practice storage at -20°C for prolonged stability.

Biological Rationale

Clozapine N-oxide (CNO; CAS 34233-69-7) is the N-oxide metabolite of the atypical antipsychotic clozapine. CNO is chemically defined as 3-chloro-6-(4-methyl-4-oxidopiperazin-4-ium-1-yl)-5H-benzo[b][1,4]benzodiazepine, with a molecular weight of 342.82 g/mol [Product data]. In native mammalian systems, CNO is considered biologically inert, showing negligible affinity for endogenous neurotransmitter receptors at research-relevant concentrations (Peng et al., 2023). The advent of designer receptors exclusively activated by designer drugs (DREADDs) allows CNO to selectively activate engineered muscarinic receptors, providing a non-invasive, reversible method to modulate specific neuronal subpopulations [See contrast]. This specificity is crucial for dissecting neural circuit function in vivo without confounding systemic effects.

Mechanism of Action of Clozapine N-oxide (CNO)

CNO selectively activates DREADDs, such as hM3Dq (Gq-coupled) and hM4Di (Gi/o-coupled), which are genetically engineered muscarinic acetylcholine receptors mutated to lose affinity for endogenous ligands but retain high affinity for CNO [Mechanistic review]. Upon systemic administration, CNO crosses the blood-brain barrier and binds to DREADDs, resulting in targeted modulation of neuronal excitability and downstream GPCR signaling. In typical usage, CNO does not activate wild-type receptors or produce behavioral effects in non-transgenic animals at doses ≤10 mg/kg (Peng et al., 2023). In vitro, CNO has been shown to reduce 5-HT2 receptor density and inhibit 5-HT-stimulated phosphoinositide hydrolysis in rat cortical and choroid plexus cultures, respectively. These effects are not observed in the absence of engineered receptors, underscoring CNO's chemogenetic specificity.

Evidence & Benchmarks

• CNO exhibits no significant activation of endogenous muscarinic or serotonergic receptors in wild-type rodents up to 10 mg/kg (Peng et al., 2023, DOI).
• Selective activation of hM3Dq DREADDs by CNO induces robust, reversible excitation of targeted neurons in hippocampal CA2 and other subregions, enabling precise behavioral modulation (Peng et al., 2023, DOI).
• CNO reduces 5-HT2 receptor density in primary rat cortical neuron cultures after 24 hours at concentrations of 1–10 μM (APExBIO product documentation, link).
• Phosphoinositide hydrolysis, stimulated by 5-HT in rat choroid plexus, is inhibited by CNO at concentrations ≥1 μM (APExBIO, link).
• CNO is optimally soluble in DMSO (>10 mM at 25°C), but insoluble in water and ethanol (APExBIO, link).

Applications, Limits & Misconceptions

Clozapine N-oxide (CNO) is extensively used in neuroscience research for chemogenetic interrogation of neuronal circuits, behavioral phenotyping, and receptor signaling studies. Applications include:

• Non-invasive, reversible manipulation of neuronal activity in vivo using DREADDs.
• Mapping functional connectivity in brain regions such as hippocampal CA2, crucial for social memory (Peng et al., 2023).
• Translational models for psychiatric disorders, including schizophrenia, by modulating GPCR pathways [See contrast: This article details anxiety/stress models, while we provide molecular benchmarks and storage parameters].
• Investigation of the caspase signaling pathway and neuromodulation [See contrast: This article provides atomic benchmarks; here, solubility/storage are detailed].

Common Pitfalls or Misconceptions

• CNO back-metabolism to clozapine: In some species, notably non-human primates and humans, CNO is partially metabolized back to clozapine, which can have off-target effects at high doses. Always verify species-specific pharmacokinetics.
• Solubility limitations: CNO is insoluble in water and ethanol; use DMSO and pre-warm to 37°C or employ ultrasonic shaking for optimal dissolution.
• Not a direct antipsychotic: CNO itself does not possess antipsychotic activity in mammals and is pharmacologically inert except in the presence of engineered receptors.
• Storage: Stock solutions are stable below -20°C but may degrade if stored in solution for extended periods. Avoid repeated freeze-thaw cycles.
• Endogenous receptor activation: At concentrations used in DREADDs studies, CNO does not activate native muscarinic or serotonergic receptors, but extremely high doses may elicit off-target effects.

Workflow Integration & Parameters

CNO is supplied by APExBIO (SKU A3317) as a powder. For experimental use, dissolve in DMSO at concentrations exceeding 10 mM. For in vivo administration, dilute further in physiological saline or buffer as appropriate, ensuring DMSO content does not exceed 0.1–0.5% in final injection volumes. Warm solutions at 37°C or use ultrasonic shaking to facilitate dissolution. Store dry powder at -20°C; stock solutions prepared in DMSO are stable at -20°C for several months, but avoid long-term solution storage. Typical dosing regimens in rodents range from 0.1–10 mg/kg intraperitoneally, with minimal behavioral effects observed in wild-type subjects [See contrast: This review details off-target profiles in wild-type animals]. Always reference the product page for updated handling protocols: Clozapine N-oxide (CNO).

Conclusion & Outlook

Clozapine N-oxide (CNO) is the benchmark chemogenetic actuator for DREADDs-mediated neuronal manipulation, offering high specificity, reversibility, and minimal off-target effects in experimental models. The molecular inertness and robust solubility profile, as provided by APExBIO, enable reliable integration in neurobiological workflows. Ongoing research continues to refine CNO's utility in translational models, especially in dissecting GPCR pathway dynamics and psychiatric disease mechanisms (Peng et al., 2023). Researchers are advised to consult up-to-date product documentation and species-specific guidelines for optimal results. For further exploration, see the contrasted articles above for advanced troubleshooting and application context.